Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Chuikyo Subcommittee to Form Consensus on Drug Prices by Autumn
March 26, 2001
- Mucosal Influenza Vaccine More Effective than Conventional Vaccines
March 26, 2001
- Mochida to Restructure Its Production System
March 26, 2001
- Chuikyo Subcommittee Starts Discussions for Next Revision of Medical Fees
March 26, 2001
- Draft Guidelines on Genetic Testing Compiled by Eight Societies
March 26, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
March 26, 2001
- 850 Questions Received Regarding Evidence for Off-label Use of Drugs
March 26, 2001
- Gene Therapy for Buerger's Disease to Be Approved Shortly
March 26, 2001
- Applications Aimed at Preventing Accidents to Be Approved Quickly
March 26, 2001
- DIAGNOSTIC NEWS IN BRIEF
March 26, 2001
- LDP Convention Calls For Radical Reform in 2002
March 26, 2001
- MEDICAL DEVICE NEWS IN BRIEF
March 26, 2001
- DPJ Starts Discussions on Healthcare Reform
March 26, 2001
- OTC NEWS IN BRIEF
March 26, 2001
- Medical Institution Information System to Go into Operation in Osaka
March 26, 2001
- Kemporen Members' Ordinary Loss to Increase to \490.4 Bil.
March 26, 2001
- PMSB to Publish Criteria for Disclosure or Non-disclosure of Information
March 26, 2001
- Aiming at \30 Billion Sales in 2005: Mr Strenger of Aventis Behring
March 26, 2001
- More Patents Exported than Imported in Pharmaceutical Field
March 26, 2001
- Roche's Herceptin Marks Step toward Tailor-made Medicine
March 26, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…